U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C28H38NO4
Molecular Weight 452.6056
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of BUTROPIUM

SMILES

CCCCOC1=CC=C(C[N@+]2(C)[C@H]3CC[C@@H]2C[C@@H](C3)OC(=O)[C@H](CO)C4=CC=CC=C4)C=C1

InChI

InChIKey=ALVDDLOWVXJXCD-OTSXCXJCSA-N
InChI=1S/C28H38NO4/c1-3-4-16-32-25-14-10-21(11-15-25)19-29(2)23-12-13-24(29)18-26(17-23)33-28(31)27(20-30)22-8-6-5-7-9-22/h5-11,14-15,23-24,26-27,30H,3-4,12-13,16-20H2,1-2H3/q+1/t23-,24+,26+,27-,29?/m1/s1

HIDE SMILES / InChI
Molecular Formula C28H37NO4
Molecular Weight 451.5977
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 3 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.mims.com/malaysia/drug/info/coliopan and http://www.genome.jp/dbget-bin/www_bget?D01491

Butropium Bromide is an anticholinergic and an antispasmodic. It is a Muscarinic receptor antagonist. The drug is used for remission of spasmodic pain in the following diseases: gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia). It is marketed in Japan under the brand name Coliopan.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
Coliopan

Approved Use

Remission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia)

Launch Date

1974
Palliative
Approved
8583
Coliopan

Approved Use

Remission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia)

Launch Date

1974
Palliative
Approved
8583
Coliopan

Approved Use

Remission of spasmodic pain in the following diseases: Gastritis, enteritis, gastric ulcer, duodenal ulcer, cholelithiasis and cholecystopathy (including cholecystitis, and cholecystic and biliary dyskinesia)

Launch Date

1974
Doses

Doses

DosePopulationAdverse events​
10 mg 3 times / day multiple, oral
Recommended
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://quest3plus.bpfk.gov.my/front-end/attachment/815/pharma/210295/V_36481_20191101_110605_D4.pdf
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: unknown
Food Status: UNKNOWN
Sources:
https://quest3plus.bpfk.gov.my/front-end/attachment/815/pharma/210295/V_36481_20191101_110605_D4.pdf
Sources:
https://quest3plus.bpfk.gov.my/front-end/attachment/815/pharma/210295/V_36481_20191101_110605_D4.pdf
4 mg 1 times / day single, intravenous
Studied dose
Dose: 4 mg, 1 times / day
Route: intravenous
Route: single
Dose: 4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
Other AEs: Palpitation, Increased thirst...
Other AEs:
Palpitation
Increased thirst
Urination difficulty (1 pt)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
AEs

AEs

AESignificanceDosePopulation
Increased thirst
4 mg 1 times / day single, intravenous
Studied dose
Dose: 4 mg, 1 times / day
Route: intravenous
Route: single
Dose: 4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
Palpitation
4 mg 1 times / day single, intravenous
Studied dose
Dose: 4 mg, 1 times / day
Route: intravenous
Route: single
Dose: 4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
Urination difficulty 1 pt
4 mg 1 times / day single, intravenous
Studied dose
Dose: 4 mg, 1 times / day
Route: intravenous
Route: single
Dose: 4 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/3478945/
PubMed

PubMed

TitleDatePubMed
Endoscopic manometry of the sphincter of Oddi in dogs. Pharmacological effects of anticholinergic and selective antimuscarinic agents.
1987-05
Sensation of aural fullness and its treatment with an autonomic nerve blocking agent.
1987
Effect of glucagon on gastric motility examined by the acetaminophen absorption method and the endoscopic procedure.
1985
Patents

Patents

US20080220441
4
US20120231047
2
US6024976
5

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Can also be administered intramuscularly http://www.ncbi.nlm.nih.gov/pubmed/7182948
Capsules 5 mg:The usual adult dosage for oral use is 6 capsules (30 mg ofbutropium bromide) daily in three divided doses. Tablets 10 mg:The usual adult dosage for oral use is 3 tablets (30 mg ofbutropium bromide) daily in three divided doses. Granules 2 %:The usual adult dosage for oral use is 1.5 g (30 mg ofbutropium bromide) daily in three divided doses.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:40:48 GMT 2025
Edited
by admin
on Mon Mar 31 18:40:48 GMT 2025
Record UNII
7WSK03KXXW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUTROPIUM
WHO-DD  
Common Name English
8-(P-BUTOXYBENZYL)-3.ALPHA.-HYDROXY-1.ALPHA.H,5.ALPHA.H-TROPANIUM (-)-TROPATE
Preferred Name English
8-AZONIABICYCLO(3.2.1)OCTANE, 8-((4-BUTOXYPHENYL)METHYL)-3-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-8-METHYL-, (3(S)-ENDO)-
Common Name English
Butropium [WHO-DD]
Common Name English
BUTROPIUM CATION
Common Name English
BUTROPIUM ION
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29704
Created by admin on Mon Mar 31 18:40:48 GMT 2025 , Edited by admin on Mon Mar 31 18:40:48 GMT 2025
Code System Code Type Description
PUBCHEM
656593
Created by admin on Mon Mar 31 18:40:48 GMT 2025 , Edited by admin on Mon Mar 31 18:40:48 GMT 2025
PRIMARY
FDA UNII
7WSK03KXXW
Created by admin on Mon Mar 31 18:40:48 GMT 2025 , Edited by admin on Mon Mar 31 18:40:48 GMT 2025
PRIMARY
EPA CompTox
DTXSID40860428
Created by admin on Mon Mar 31 18:40:48 GMT 2025 , Edited by admin on Mon Mar 31 18:40:48 GMT 2025
PRIMARY
EVMPD
SUB00923MIG
Created by admin on Mon Mar 31 18:40:48 GMT 2025 , Edited by admin on Mon Mar 31 18:40:48 GMT 2025
PRIMARY
CAS
107080-63-7
Created by admin on Mon Mar 31 18:40:48 GMT 2025 , Edited by admin on Mon Mar 31 18:40:48 GMT 2025
PRIMARY
NCI_THESAURUS
C83569
Created by admin on Mon Mar 31 18:40:48 GMT 2025 , Edited by admin on Mon Mar 31 18:40:48 GMT 2025
PRIMARY
SMS_ID
100000084862
Created by admin on Mon Mar 31 18:40:48 GMT 2025 , Edited by admin on Mon Mar 31 18:40:48 GMT 2025
PRIMARY
DRUG CENTRAL
456
Created by admin on Mon Mar 31 18:40:48 GMT 2025 , Edited by admin on Mon Mar 31 18:40:48 GMT 2025
PRIMARY
Related Record Type Details
Structure of BUTROPIUM
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966